文献速递乳腺癌

戈沙妥珠单抗用于激素受体阳性/人表皮生长因子受体2阴性转移性乳腺癌

Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.
PubMed 文献 · J Clin Oncol · 2022-08-26

这项全球随机III期研究在内分泌耐药、经化疗的HR+/HER2-局部复发不可手术或转移性乳腺癌中比较戈沙妥珠单抗(SG)与医生选择化疗。SG组272例、化疗组271例,主要终点盲法独立中心评估的无进展生存期(PFS)达到,疾病进展或死亡风险降低34%(HR 0.66,95%CI 0.53-0.83,P=.0003),中位PFS SG组5.5个月 vs 化疗组4.0个月。总生存首次计划期中分析尚未成熟(HR 0.84,P=.14)。

要点

  • SG较医生选择化疗显著改善PFS:中位5.5个月 vs 4.0个月,HR 0.66(95%CI 0.53-0.83,P=.0003)。
  • 6个月PFS率SG组46% vs 化疗组30%,12个月PFS率21% vs 7%。
  • ≥3级治疗相关不良事件:中性粒细胞减少SG组51% vs 化疗组38%,腹泻9% vs 1%。

核心结论

  • 在经重度治疗、内分泌耐药的HR+/HER2-晚期乳腺癌且治疗选择有限的患者中,SG较化疗显示统计学显著的PFS获益,安全性可控。

研究设计与样本

  • 全球、随机、III期研究,比较SG与医生选择化疗(艾日布林、长春瑞滨、卡培他滨或吉西他滨)。
  • 入组内分泌耐药、经化疗的HR+/HER2-局部复发不可手术或转移性乳腺癌患者,随机分配至SG组(n=272)或化疗组(n=271)。
  • 主要终点为盲法独立中心评估的PFS。

主要发现

  • 中位年龄56岁,95%有内脏转移,99%既往用过细胞周期蛋白依赖性激酶4/6抑制剂,晚期疾病化疗中位线数为3线。
  • 主要终点达到:疾病进展或死亡风险降低34%(HR 0.66,95%CI 0.53-0.83,P=.0003)。
  • 中位PFS:SG组5.5个月(95%CI 4.2-7.0)vs 化疗组4.0个月(95%CI 3.1-4.4)。
  • 6个月PFS率:SG组46%(95%CI 39-53)vs 化疗组30%(95%CI 24-37);12个月PFS率:SG组21%(95%CI 15-28)vs 化疗组7%(95%CI 3-14)。
  • 总生存首次计划期中分析尚未成熟:HR 0.84,P=.14。

临床怎么用

  • 原文结论为SG在经重度治疗、内分泌耐药的HR+/HER2-晚期乳腺癌且治疗选择有限的患者中较化疗显示统计学显著的PFS获益,安全性可控。

局限性

  • 总生存首次计划期中分析尚未成熟(HR 0.84,P=.14)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) endocrine-resistant metastatic breast cancer is treated with sequential single-agent chemotherapy with poor outcomes. Sacituzumab govitecan (SG) is a first-in-class antibody-drug conjugate with an SN-38 payload targeting trophoblast cell-surface antigen 2, an epithelial antigen expressed in breast cancer. METHODS: In this global, randomized, phase III study, SG was compared with physician's choice chemotherapy (eribulin, vinorelbine, capecitabine, or gemcitabine) in endocrine-resistant, chemotherapy-treated HR+/HER2- locally recurrent inoperable or metastatic breast cancer. The primary end point was progression-free survival (PFS) by blinded independent central review. RESULTS: Patients were randomly assigned to receive SG (n = 272) or chemotherapy (n = 271). The median age was 56 years, 95% had visceral metastases, and 99% had a prior cyclin-dependent kinase 4/6 inhibitor, with three median lines of chemotherapy for advanced disease. Primary end point was met with a 34% reduction in risk of progression or death (hazard ratio, 0.66 [95% CI, 0.53 to 0.83; P = .0003]). The median PFS was 5.5 months (95% CI, 4.2 to 7.0) with SG and 4.0 months (95% CI, 3.1 to 4.4) with chemotherapy; the PFS at 6 and 12 months was 46% (95% CI, 39 to 53) v 30% (95% CI, 24 to 37) and 21% (95% CI, 15 to 28) v 7% (95% CI, 3 to 14), respectively. Median overall survival (first planned interim analysis) was not yet mature (hazard ratio, 0.84; P = .14). Key grade ≥ 3 treatment-related adverse events (SG v chemotherapy) were neutropenia (51% v 38%) and diarrhea (9% v 1%). CONCLUSION: SG demonstrated statistically significant PFS benefit over chemotherapy, with a manageable safety profile in patients with heavily pretreated, endocrine-resistant HR+/HER2- advanced breast cancer and limited treatment options.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Rugo HS, Bardia A, Marmé F, et al. Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. J Clin Oncol. 2022. PMID: 36027558. doi:10.1200/JCO.22.01002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。